Please provide your email address to receive an email when new articles are posted on . Treatment with adaptive servo-ventilation for 12 months improved disease-specific quality of life scores. At 12 ...
Using Philips PAP solutions, results resurface conversation around ASV therapy use for complex sleep apnea and its potential to improve quality of life Amsterdam, the Netherlands – Royal Philips (NYSE ...
On May 15, 2015, Respironics, Inc., a Philips business, provided the following response to ResMed's Update on Phase IV SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy in Central Sleep Apnea ...
In research presented at the American Thoracic Society 2024 International Conference, Benjafield and colleagues explored the treatment of sleep-disordered breathing with adaptive sero-ventilation (ASV ...
Please provide your email address to receive an email when new articles are posted on . LONDON — Adaptive servo-ventilation had no significant impact on the primary composite endpoint of all-cause ...
ResMed announced primary results from a multicenter, randomized controlled phase II trial known as CAT-HF presented at the European Society of Cardiology's 2016 Annual Heart Failure Congress. CAT-HF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback